1. Home
  2. GABC vs MPLT Comparison

GABC vs MPLT Comparison

Compare GABC & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo German American Bancorp Inc.

GABC

German American Bancorp Inc.

HOLD

Current Price

$51.06

Market Cap

1.8B

Sector

Finance

ML Signal

HOLD

Logo MapLight Therapeutics Inc.

MPLT

MapLight Therapeutics Inc.

HOLD

Current Price

$13.37

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GABC
MPLT
Founded
1910
2018
Country
United States
United States
Employees
N/A
133
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.7B
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
GABC
MPLT
Price
$51.06
$13.37
Analyst Decision
Buy
Strong Buy
Analyst Count
3
7
Target Price
$47.67
$32.67
AVG Volume (30 Days)
152.3K
1.4M
Earning Date
04-27-2026
05-28-2026
Dividend Yield
2.88%
N/A
EPS Growth
8.13
N/A
EPS
0.88
N/A
Revenue
$487,401,000.00
N/A
Revenue This Year
$16.78
N/A
Revenue Next Year
$3.98
N/A
P/E Ratio
$58.00
N/A
Revenue Growth
37.80
N/A
52 Week Low
$37.19
$9.10
52 Week High
$52.23
$40.43

Technical Indicators

Market Signals
Indicator
GABC
MPLT
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
GABC
MPLT

About GABC German American Bancorp Inc.

German American Bancorp Inc is a bank holding company. The lines of business include the core banking segment and the wealth management segment. The core banking segment involves attracting deposits from the general public and using those funds to originate consumer, commercial, and agricultural real estate, and residential mortgage loans. These core banking activities also include the sale of residential mortgage loans in the secondary market. Wealth management services, which involve providing trust, investment advisory, brokerage, and retirement planning services to customers. The company generates the majority of its revenue from the core banking segment.

About MPLT MapLight Therapeutics Inc.

MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.

Share on Social Networks: